Please wait while the formulary information is being retrieved.
Drug overview for GLUCAGON HCL (glucagon hcl):
Generic name: GLUCAGON HCL
Drug class: Glucagon and Analogs
Therapeutic class: Diagnostic Agents
Glucagon, an antihypoglycemic agent, is a hormone synthesized and secreted by the alpha2 cells of the pancreatic islets of Langerhans that increases blood glucose concentration by stimulating hepatic glycogenolysis.
No enhanced Uses information available for this drug.
Generic name: GLUCAGON HCL
Drug class: Glucagon and Analogs
Therapeutic class: Diagnostic Agents
Glucagon, an antihypoglycemic agent, is a hormone synthesized and secreted by the alpha2 cells of the pancreatic islets of Langerhans that increases blood glucose concentration by stimulating hepatic glycogenolysis.
No enhanced Uses information available for this drug.
DRUG IMAGES
GLUCAGON 1 MG VIAL
The following indications for GLUCAGON HCL (glucagon hcl) have been approved by the FDA:
Indications:
Gastrointestinal radiography adjunct
Hypoglycemic disorder
Professional Synonyms:
Adjunct gastrointestinal radiography
GI radiography adjunct
Hypoglycemia
Indications:
Gastrointestinal radiography adjunct
Hypoglycemic disorder
Professional Synonyms:
Adjunct gastrointestinal radiography
GI radiography adjunct
Hypoglycemia
The following dosing information is available for GLUCAGON HCL (glucagon hcl):
Glucagon has been used with some success as a cardiac stimulant for the management of cardiac manifestations (e.g., bradycardia, hypotension, myocardial depression) associated with beta-adrenergic blocking agent overdosage+ or calcium-channel blocking agent overdosage+. Resuscitation following cardiac arrest from beta-blocker or calcium-channel blocker overdosage should follow standard basic life support (BLS) and advanced cardiac life support (ACLS) algorithms. Some data indicate that administration of glucagon may be useful in treating severe cardiovascular instability associated with beta-blocker overdosage that is refractory to standard measures, including vasopressors, and some experts state that such use is reasonable.
Evidence of efficacy in calcium-channel blocker overdosage is more limited; however, some experts state that treatment with glucagon also may be considered in patients with severe, refractory cardiovascular instability associated with calcium-channel blocker overdosage.
Dosage of glucagon or glucagon hydrochloride is expressed in terms of glucagon.
For the treatment of severe hypoglycemia, the recommended subcutaneous, IM, or IV dose of glucagon administered as reconstituted glucagon for injection is 1 mg in adults and children weighing at least 20 kg and 0.5 mg in children weighing less than 20 kg; alternatively, a dose of 20-30 mcg/kg can be administered in children weighing less than 20 kg.
For the treatment of severe hypoglycemia, the recommended subcutaneous, IM, or IV dose of glucagon administered as reconstituted glucagon hydrochloride for injection (e.g., GlucaGen(R)) is 1 mg in adults and children weighing 25 kg or more and 0.5 mg in children weighing less than 25 kg. If the weight of the child is unknown, children younger than 6 years of age should receive a dose of 0.5
mg and those 6 years of age or older should receive 1 mg.
When glucagon prefilled syringes or auto-injectors (Gvoke(R)) are used for the treatment of severe hypoglycemia, the recommended subcutaneous dose of glucagon in adults and adolescents at least 12 years of age is 1 mg; in children 2 to less than 12 years of age, the recommended subcutaneous dose is 1 mg in those weighing at least 45 kg and 0.5 mg in those weighing less than 45 kg.
If the patient has not responded to the initial dose of glucagon after 15 minutes, an additional dose of the drug (equivalent to the initial dose) may be administered.
For the treatment of severe hypoglycemia in adults and children 4 years of age and older, the recommended intranasal dosage of glucagon is 3 mg (one actuation of the Baqsimi(R) intranasal device) administered into one nostril. If the patient has not responded to the initial dose after 15 minutes, a second 3-mg dose may be administered.
For the management of cardiac manifestations of beta-blocker overdosage+ in adults, glucagon has been administered as a direct IV injection at a dose of 3-10 mg administered slowly over 3-5 minutes, followed by an IV infusion of 2-5 mg/hour. Because of the amount of glucagon required to sustain this therapy, the availability of an adequate supply of glucagon must be considered.
For the management of cardiac manifestations of calcium-channel blocker overdosage+ in adults, glucagon has been administered as a direct IV injection at a dose of 3-10 mg over 3-5 minutes, followed by an IV infusion of 3-5 mg/hour.
Evidence of efficacy in calcium-channel blocker overdosage is more limited; however, some experts state that treatment with glucagon also may be considered in patients with severe, refractory cardiovascular instability associated with calcium-channel blocker overdosage.
Dosage of glucagon or glucagon hydrochloride is expressed in terms of glucagon.
For the treatment of severe hypoglycemia, the recommended subcutaneous, IM, or IV dose of glucagon administered as reconstituted glucagon for injection is 1 mg in adults and children weighing at least 20 kg and 0.5 mg in children weighing less than 20 kg; alternatively, a dose of 20-30 mcg/kg can be administered in children weighing less than 20 kg.
For the treatment of severe hypoglycemia, the recommended subcutaneous, IM, or IV dose of glucagon administered as reconstituted glucagon hydrochloride for injection (e.g., GlucaGen(R)) is 1 mg in adults and children weighing 25 kg or more and 0.5 mg in children weighing less than 25 kg. If the weight of the child is unknown, children younger than 6 years of age should receive a dose of 0.5
mg and those 6 years of age or older should receive 1 mg.
When glucagon prefilled syringes or auto-injectors (Gvoke(R)) are used for the treatment of severe hypoglycemia, the recommended subcutaneous dose of glucagon in adults and adolescents at least 12 years of age is 1 mg; in children 2 to less than 12 years of age, the recommended subcutaneous dose is 1 mg in those weighing at least 45 kg and 0.5 mg in those weighing less than 45 kg.
If the patient has not responded to the initial dose of glucagon after 15 minutes, an additional dose of the drug (equivalent to the initial dose) may be administered.
For the treatment of severe hypoglycemia in adults and children 4 years of age and older, the recommended intranasal dosage of glucagon is 3 mg (one actuation of the Baqsimi(R) intranasal device) administered into one nostril. If the patient has not responded to the initial dose after 15 minutes, a second 3-mg dose may be administered.
For the management of cardiac manifestations of beta-blocker overdosage+ in adults, glucagon has been administered as a direct IV injection at a dose of 3-10 mg administered slowly over 3-5 minutes, followed by an IV infusion of 2-5 mg/hour. Because of the amount of glucagon required to sustain this therapy, the availability of an adequate supply of glucagon must be considered.
For the management of cardiac manifestations of calcium-channel blocker overdosage+ in adults, glucagon has been administered as a direct IV injection at a dose of 3-10 mg over 3-5 minutes, followed by an IV infusion of 3-5 mg/hour.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for GLUCAGON HCL (glucagon hcl):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Glucagon (Diagnostic)/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Glucagon and anticholinergic agents may have additive effects on inhibition of gastrointestinal motility.(1) CLINICAL EFFECTS: Concurrent use of glucagon with anticholinergic agents may increase the risk of gastrointestinal hypomotility, including constipation and bowel complications.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent use of glucagon as a diagnotic aid is not recommended with the use of anticholinergic agents.(1) If concurrent use is necessary, evaluate the patient's bowel function. Monitor for symptoms of constipation and gastrointestinal hypomotility. DISCUSSION: Both glucagon and anticholinergic agents may have additive effects on inhibition of gastrointestinal motility and increase the risk of gastrointestinal adverse effects.(1) |
ADASUVE, AMITRIPTYLINE HCL, AMOXAPINE, ANAFRANIL, ANASPAZ, ANTIVERT, ATROPEN, ATROPINE SULFATE, ATROVENT HFA, BELLADONNA, BELLADONNA LEAF POWDER, BELLADONNA-OPIUM, BENZTROPINE MESYLATE, BEVESPI AEROSPHERE, BONJESTA, BREZTRI AEROSPHERE, BROMFED DM, BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE-PSEUDOEPHED-DM, CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE ER, CHLORDIAZEPOXIDE-AMITRIPTYLINE, CHLORDIAZEPOXIDE-CLIDINIUM, CHLORPHENIRAMINE MALEATE, CIMETIDINE, CLEMASTINE FUMARATE, CLEMASZ, CLIDINIUM BROMIDE, CLOMIPRAMINE HCL, CLOZAPINE, CLOZAPINE ODT, CLOZARIL, COBENFY, COBENFY STARTER PACK, COMBIVENT RESPIMAT, CUVPOSA, CYCLOPENTOLATE HCL, CYPROHEPTADINE HCL, DARIFENACIN ER, DARTISLA, DESIPRAMINE HCL, DEXCHLORPHENIRAMINE MALEATE, DICLEGIS, DICYCLOMINE HCL, DIMENHYDRINATE, DIPHEN, DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE-0.9% NACL, DIPHENOXYLATE-ATROPINE, DONNATAL, DOXEPIN HCL, DOXYLAMINE SUCC-PYRIDOXINE HCL, DOXYLAMINE SUCCINATE, DUODOTE, ED-SPAZ, FESOTERODINE FUMARATE ER, FLAVOXATE HCL, GLYCATE, GLYCOPYRROLATE, GLYCOPYRROLATE-STERILE WATER, GLYCOPYRROLATE-WATER, GLYRX-PF, HALDOL DECANOATE 100, HALDOL DECANOATE 50, HALOPERIDOL, HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE 100, HALOPERIDOL LACTATE, HOMATROPINE METHYLBROMIDE, HYCODAN, HYDROCODONE-CHLORPHENIRAMNE ER, HYDROCODONE-HOMATROPINE MBR, HYDROMET, HYDROXYZINE HCL, HYDROXYZINE PAMOATE, HYOSCYAMINE SULFATE, HYOSCYAMINE SULFATE ER, HYOSCYAMINE SULFATE SR, HYOSYNE, IMIPRAMINE HCL, IMIPRAMINE PAMOATE, IPRATROPIUM BROMIDE, IPRATROPIUM-ALBUTEROL, ISOPROPAMIDE IODIDE, KARBINAL ER, LEVBID, LEVSIN, LEVSIN-SL, LIBRAX, LOMOTIL, LOXAPINE, MB CAPS, ME-NAPHOS-MB-HYO 1, MECLIZINE HCL, METHSCOPOLAMINE BROMIDE, MOTOFEN, NORGESIC, NORGESIC FORTE, NORPRAMIN, NORTRIPTYLINE HCL, NULEV, ORPHENADRINE CITRATE, ORPHENADRINE CITRATE ER, ORPHENADRINE-ASPIRIN-CAFFEINE, ORPHENGESIC FORTE, OSCIMIN, OSCIMIN SL, OXCARBAZEPINE, OXCARBAZEPINE ER, OXTELLAR XR, OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE ER, OXYTROL, PAMELOR, PERPHENAZINE-AMITRIPTYLINE, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PREVDUO, PROPANTHELINE BROMIDE, PROTRIPTYLINE HCL, PYRILAMINE MALEATE, RESPA A.R., ROBINUL, ROBINUL FORTE, RYCLORA, RYVENT, SCOPOLAMINE, SCOPOLAMINE HYDROBROMIDE, SCOPOLAMINE METHYL NITRATE, SILENOR, SOLIFENACIN SUCCINATE, SPIRIVA HANDIHALER, SPIRIVA RESPIMAT, STIOLTO RESPIMAT, SYMAX, SYMAX DUOTAB, SYMAX-SL, SYMAX-SR, TIOTROPIUM BROMIDE, TOLTERODINE TARTRATE, TOLTERODINE TARTRATE ER, TOVIAZ, TRANSDERM-SCOP, TRIFLUOPERAZINE HCL, TRIHEXYPHENIDYL HCL, TRILEPTAL, TRIMIPRAMINE MALEATE, TRIPROLIDINE HCL, TROPICAMIDE, TROSPIUM CHLORIDE, TROSPIUM CHLORIDE ER, TUXARIN ER, URELLE, URETRON D-S, URIBEL TABS, URIMAR-T, URNEVA, URO-MP, URO-SP, UROGESIC-BLUE, URYL, VERSACLOZ, VESICARE, VESICARE LS |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Coumarin Anticoagulants/Glucagon, Dasiglucagon SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Not defined. CLINICAL EFFECTS: Excess hypoprothrombinemia and possible bleeding complications. PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: If the duration of glucagon/dasiglucagon therapy is one day, a clinically important interaction is unlikely. Avoid using multiple doses of glucagon/dasiglucagon in anticoagulated patients. If this combination is necessary, decrease the warfarin dose prior to glucagon/dasiglucagon dosing. Monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin and/or hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform INR to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: If the duration of glucagon/dasiglucagon therapy is one day, a clinically important interaction is unlikely. However, the potentiation effects of glucagon/dasiglucagon on the anticoagulant effect of warfarin seems to occur rapidly and can reverse within one day of stopping glucagon. |
ANISINDIONE, DICUMAROL, JANTOVEN, WARFARIN SODIUM |
The following contraindication information is available for GLUCAGON HCL (glucagon hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 4 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Diabetes mellitus |
| Glucagonoma |
| Insulinoma |
| Pheochromocytoma |
There are 0 moderate contraindications.
The following adverse reaction information is available for GLUCAGON HCL (glucagon hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 7 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Acute respiratory distress syndrome Anaphylaxis Dyspnea Hypersensitivity drug reaction Hypertension Hypotension Necrolytic migratory erythema |
There are 14 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Headache disorder Injection site sequelae Nausea Vomiting |
Acute abdominal pain Diarrhea Dizziness Drowsy General weakness Pallor Urticaria |
| Rare/Very Rare |
|---|
|
Hyperglycemia Skin rash Tachycardia |
The following precautions are available for GLUCAGON HCL (glucagon hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for GLUCAGON HCL (glucagon hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for GLUCAGON HCL (glucagon hcl)'s list of indications:
| Hypoglycemic disorder | |
| E08.64 | Diabetes mellitus due to underlying condition with hypoglycemia |
| E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
| E09.64 | Drug or chemical induced diabetes mellitus with hypoglycemia |
| E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
| E10.64 | Type 1 diabetes mellitus with hypoglycemia |
| E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma |
| E11.64 | Type 2 diabetes mellitus with hypoglycemia |
| E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma |
| E13.64 | Other specified diabetes mellitus with hypoglycemia |
| E13.649 | Other specified diabetes mellitus with hypoglycemia without coma |
| E16.0 | Drug-induced hypoglycemia without coma |
| E16.1 | Other hypoglycemia |
| E16.2 | Hypoglycemia, unspecified |
| P70.3 | Iatrogenic neonatal hypoglycemia |
| P70.4 | Other neonatal hypoglycemia |
Formulary Reference Tool